Discover
FBRX
Forte Biosciences, Inc.
21.32
2 x 15.39
2 x 26.38
bid
ask
+
0.07
0.33%
2 @ 04:00 PM
21.32 +0.00 (0.00%)
| Ytd | -21.82% | |
| 1y | 71.38% |
20.52
day range
21.75
9.10
52 week range
35.80
| Open | 21.31 | Prev Close | 21.25 | Low | 20.52 | High | 21.75 | Mkt Cap | 436.61M |
| Vol | 339.07K | Avg Vol | 346.89K | EPS | -4.58 | P/E | N/A | Forward P/E | -1.04 |
| Beta | 1.46 | Short Ratio | 0.09 | Inst. Own | 54.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 21.98 | 200-d Avg | 22.68 | 1yr Est | 107.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -6.75 | -4.54 | 2.21 | 32.74% |
| 2024-08-14 | 2024-06 | -4 | -6.75 | -2.75 | -68.75% |
| 2024-05-13 | 2024-03 | 0 | -4 | N/A | N/A |
| 2024-03-18 | 2023-12 | 0 | -1 | N/A | N/A |
| 2023-11-13 | 2023-09 | 0 | -6.5 | N/A | N/A |
| 2023-08-14 | 2023-06 | 0 | -10.5 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-04 | Chardan Capital | Upgrade | Buy | Buy |
| 2024-11-15 | Chardan Capital | Upgrade | Buy | Buy |
| 2024-08-19 | Chardan Capital | Upgrade | Buy | Buy |
| 2024-05-30 | Brookline Capital | Upgrade | Buy | |
| 2024-04-08 | Ladenburg Thalmann | Upgrade | Neutral | Buy |
| 2021-09-20 | Chardan Capital | Upgrade | Sell | Neutral |
Profile
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-12-28 | CHEN HUBERT C | President | 93.41K | Conversion of Exercise of derivative security |
| 2021-01-12 | DARCY THOMAS E | Director | 27.00K | Conversion of Exercise of derivative security |
| 2020-02-25 | GRUBER HARRY E | Officer and Director | 441.44K | Stock Award(Grant) |
| 2023-07-30 | GRYSKA DAVID W | Director | 148.51K | Stock Award(Grant) |
| 2019-05-29 | HASNAIN FAHEEM | Director | 0.00 | Purchase |
| 2023-07-30 | KORNFELD STEVEN | Director | 99.01K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Tybourne Capital Management (HK) Limited | 144.98K | 2.76M | 2.27% |
| 2024-09-29 | BVF Inc. | 119.28K | 2.27M | 1.87% |
| 2024-09-29 | Perceptive Advisors Llc | 95.74K | 1.82M | 1.50% |
| 2024-09-29 | Fred Alger Management, LLC | 82.70K | 1.57M | 1.29% |
| 2024-09-29 | Cable Car Capital LLC | 81.28K | 1.55M | 1.27% |
| 2024-09-29 | Farallon Capital Management LLC | 72.41K | 1.38M | 1.13% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-07-30 | Alger Health Sciences Fund | 47.71K | 907.04K | 0.75% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 19.50K | 370.64K | 0.30% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 6.63K | 126.07K | 0.10% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 5.98K | 113.66K | 0.09% |
| 2024-10-30 | Fidelity NASDAQ Composite Index ETF | 4.40K | 83.61K | 0.07% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 1.58K | 30.05K | 0.02% |
Split
| Split | Date |
|---|---|
| 1 : 25 | 2024-08-28 |
| 1 : 15 | 2020-06-16 |